Marc Steben (Canada)
Canadian HPV prevention network -
Presenter of 4 Presentations
Diagnosing and management of HPV-associated vulvar disease (ID 31)
Session Time
11:00 - 12:25
Session Type
Clinical Science
Lecture Time
11:23 - 11:43
CANADA’S ROLE IN ACCELERATING GLOBAL ELIMINATION OF CERVICAL CANCER (ID 211)
Session Time
10:00 - 17:00
Session Type
Poster Viewing - 20-24 July
Session Name
Public Health / Epidemiology / Global Impact of HPV and Cervical Cancer Prevention
Lecture Time
10:09 - 10:10
Introduction
Elimination of cervical cancer by 2030 is a key global objective proposed by WHO. Canadian experts have determined that, to achieve this goal, the Montreal Global HPV prevention objectives need to be met in the targeted population;
· 90% of girls fully vaccinated with the HPV vaccine by 15 years old;
· 90% of women screened with an HPV test; and
· 90% of women identified with cervical disease receive treatment and care.
Methods
A group of 20 prominent international HPV/cervical cancer experts attended a planning workshop and created a report on Canada’s role in accelerating global elimination of cervical cancer.
National/international recommendations have been made to the Canadian Government that would enable Canadians to become major contributors in efforts to attain the goals set by WHO.
Results
Canadian experts have the scientific expertise and the tools to reach the WHO 2030 objective of decreasing cervical cancer incidence to fewer than 4 per 100,000. The main challenge in the planning of cervical cancer elimination is to secure funding and political support.
In order to reach this ambitious objective, innovative approaches must be developed with community leaders to bring the reality of cervical cancer elimination to all communities but especially to communities that experience higher rates of cervical cancer.
Conclusions
Canada should assume international leadership for cervical cancer elimination. Over 100 recommendations for action have been proposed within this important document. Two powerful tools exist for this drive to cervical cancer elimination by 2030: HPV prophylactic vaccines and cervical cancer screening. To take the greatest advantage of these tools, knowledgeable experts must be involved and efforts expedited to implement at least some of these recommendations. If there are delays, the international cervical cancer elimination objective will not be met, with the possible exception of a few rich countries that are already approaching the goal.
Hide
Introduction by Chairs (ID 91)
Session Time
13:30 - 14:55
Session Type
Public Health
Lecture Time
13:30 - 13:33
Education Committee (ID 1756)
Session Time
16:00 - 17:40
Session Type
Networking Events
Lecture Time
17:20 - 17:30
Moderator of 3 Sessions
Session Type
Public Health
Session Time
13:30 - 14:55
Session Type
Interdisciplinary
Session Time
15:30 - 16:55
Session Type
Public Health Oral Session
Session Time
11:35 - 13:00
[{"name":"DEVELOPMENT AND EVALUATION OF AN ONLINE CONTINUING EDUCATION MODULE TO INCREASE HEALTHCARE PROVIDER SELF-EFFICACY TO MAKE STRONG HPV VACCINE RECOMMENDATIONS TO EAST AFRICAN IMMIGRANT FAMILIES \u003Csmall\u003E(ID 603)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":603,"presentation":"DEVELOPMENT AND EVALUATION OF AN ONLINE CONTINUING EDUCATION MODULE TO INCREASE HEALTHCARE PROVIDER SELF-EFFICACY TO MAKE STRONG HPV VACCINE RECOMMENDATIONS TO EAST AFRICAN IMMIGRANT FAMILIES \u003Csmall\u003E(ID 603)\u003C\/small\u003E","session":"Oral Session 7: VACCINATION III. Implementation, dissemination, and communication","presenter":"Rachel L. Winer (United States of America)","photo":""},"playlist":[{"name":"DEVELOPMENT AND EVALUATION OF AN ONLINE CONTINUING EDUCATION MODULE TO INCREASE HEALTHCARE PROVIDER ","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/Rachel Winer - IPVC20 - PRESENTATION id 603.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/69\/Rachel Winer - IPVC20 - PRESENTATION id 603.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/96388DCA.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/Rachel Winer - IPVC20 - PRESENTATION id 603.vtt"}]},{"name":"HPV VACCINATION RATES IN A RANDOMIZED TRIAL EVALUATING A SOCIAL MEDIA CAMPAIGN WITH MOTHERS OF DAUGHTERS AGED 14-17 IN THE USA \u003Csmall\u003E(ID 645)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":645,"presentation":"HPV VACCINATION RATES IN A RANDOMIZED TRIAL EVALUATING A SOCIAL MEDIA CAMPAIGN WITH MOTHERS OF DAUGHTERS AGED 14-17 IN THE USA \u003Csmall\u003E(ID 645)\u003C\/small\u003E","session":"Oral Session 7: VACCINATION III. Implementation, dissemination, and communication","presenter":"David Buller (United States of America)","photo":""},"playlist":[{"name":"HPV VACCINATION RATES IN A RANDOMIZED TRIAL EVALUATING A SOCIAL MEDIA CAMPAIGN WITH MOTHERS OF DAUGH","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/David Buller 645.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/69\/David Buller 645.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/FCB13EA8.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/David Buller 645.vtt"}]},{"name":"EVALUATING THE IMPLEMENTATION OF AN HPV VACCINE SCHOOL ENTRY REQUIREMENT POLICY USING PROVIDER-VERIFIED DATA \u003Csmall\u003E(ID 496)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":496,"presentation":"EVALUATING THE IMPLEMENTATION OF AN HPV VACCINE SCHOOL ENTRY REQUIREMENT POLICY USING PROVIDER-VERIFIED DATA \u003Csmall\u003E(ID 496)\u003C\/small\u003E","session":"Oral Session 7: VACCINATION III. Implementation, dissemination, and communication","presenter":"Gregory Zimet (United States of America)","photo":""},"playlist":[{"name":"EVALUATING THE IMPLEMENTATION OF AN HPV VACCINE SCHOOL ENTRY REQUIREMENT POLICY USING PROVIDER-VERIF","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/496.Gregory Zimet.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/69\/496.Gregory Zimet.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/925339F4.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/496.Gregory Zimet.vtt"}]},{"name":"HIGH VACCINE EFFECTIVENESS AGAINST PERSISTENT INFECTIONS UP TO EIGHT YEARS POST THREE DOSES OF BIVALENT HPV VACCINATION IN THE NETHERLANDS \u003Csmall\u003E(ID 715)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":715,"presentation":"HIGH VACCINE EFFECTIVENESS AGAINST PERSISTENT INFECTIONS UP TO EIGHT YEARS POST THREE DOSES OF BIVALENT HPV VACCINATION IN THE NETHERLANDS \u003Csmall\u003E(ID 715)\u003C\/small\u003E","session":"Oral Session 7: VACCINATION III. Implementation, dissemination, and communication","presenter":"Joske Hoes (Netherlands)","photo":""},"playlist":[{"name":"HIGH VACCINE EFFECTIVENESS AGAINST PERSISTENT INFECTIONS UP TO EIGHT YEARS POST THREE DOSES OF BIVAL","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/GMT20200526-100012_Zoom-Recor_1920x1080.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/69\/GMT20200526-100012_Zoom-Recor_1920x1080.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/55F3A9BE.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/GMT20200526-100012_Zoom-Recor_1920x1080.vtt"}]},{"name":"STRONG REDUCTION IN PREVALENCE OF HPV 16\/18 AND CLOSELY RELATED HPV TYPES IN SEXUALLY ACTIVE ADOLESCENT WOMEN FOLLOWING THE INTRODUCTION OF HPV VACCINATION IN ARGENTINA. \u003Csmall\u003E(ID 163)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":163,"presentation":"STRONG REDUCTION IN PREVALENCE OF HPV 16\/18 AND CLOSELY RELATED HPV TYPES IN SEXUALLY ACTIVE ADOLESCENT WOMEN FOLLOWING THE INTRODUCTION OF HPV VACCINATION IN ARGENTINA. \u003Csmall\u003E(ID 163)\u003C\/small\u003E","session":"Oral Session 7: VACCINATION III. Implementation, dissemination, and communication","presenter":"Rita M. Correa (Argentina)","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/ipvc20\/persons\/photos\/1791.jpg"},"playlist":[{"name":"STRONG REDUCTION IN PREVALENCE OF HPV 16\/18 AND CLOSELY RELATED HPV TYPES IN SEXUALLY ACTIVE ADOLESC","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/Rita Mariel Correa - IPVC20 - Presentation 163.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/69\/Rita Mariel Correa - IPVC20 - Presentation 163.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/521160.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/Rita Mariel Correa - IPVC20 - Presentation 163.vtt"}]},{"name":"EFFECTIVENESS AND COST-EFFECTIVENESS OF POINT-OF-CARE HPV-DNA TESTING AND SAME-DAY TREATMENT IN THE HIGH-BURDEN, LOW-RESOURCE SETTING OF PAPUA NEW GUINEA \u003Csmall\u003E(ID 981)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":981,"presentation":"EFFECTIVENESS AND COST-EFFECTIVENESS OF POINT-OF-CARE HPV-DNA TESTING AND SAME-DAY TREATMENT IN THE HIGH-BURDEN, LOW-RESOURCE SETTING OF PAPUA NEW GUINEA \u003Csmall\u003E(ID 981)\u003C\/small\u003E","session":"Oral Session 7: VACCINATION III. Implementation, dissemination, and communication","presenter":"Diep Thi Ngoc Nguyen (Australia)","photo":""},"playlist":[{"name":"EFFECTIVENESS AND COST-EFFECTIVENESS OF POINT-OF-CARE HPV-DNA TESTING AND SAME-DAY TREATMENT IN THE ","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/2nd Recording NEW _Diep Nguye IPVC 20 p 981.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/69\/2nd Recording NEW _Diep Nguye IPVC 20 p 981.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/B1EB592E.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/69\/2nd Recording NEW _Diep Nguye IPVC 20 p 981.vtt"}]}]
{"type":2,"code":"7E32UU02c"}
[session]
[presentation]
[presenter]